In 2004, Kirill Peskov graduated from the Biophysics Department at the Biological Faculty of Moscow State University. Following a postgraduate fellowship at the Institute of Theoretical and Experimental Biophysics, the Russian Academy of Science, Kirill obtained his Ph.D. in Bioinformatics.
Between 2002 and 2011, Kirill Peskov accumulated several years of modeling experience at the Institute for Systems Biology, Moscow, working with several pharma and biotech companies on translational problems involving modeling of quantitative systems pharmacology and mechanistic PKPD, signal transduction and biomarkers.
In mid-2011, Kirill started as one of the pioneers in the newly created R&D Modeling & Simulation group at Novartis Pharma, Moscow. This group is an integral part of the global M&S function at Novartis, worldwide. From Moscow, Kirill coordinates strategic developments for M&S within the Company. He also leads several global R&D projects, based on Drug-Disease modeling applications in the ophthalmic and neuroscience areas.
Starting May 2015 Kirill has founded “M&S Decisions” LLC modeling consultancy, supporting Global pharma companies with systems pharmacology and pharmacometrics expertise. In 2015 “M&S Decisions” LLC became a strategic R&D partner for AstraZeneca Company, developing predictive modeling platforms for the development of the new drugs in immuneoncology, cardiovascular disorders and diabetes.